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Exploring the effects of cannabidiol on RAW 264.7
macrophage cell viability and
inflammatory cytokine IL-6 production
V. Danchine, C. Caldari-Torres Ph. D.




Cannabidiol (CBD) is a non-psychoactive derivative from the marijuana plant. Recently, there has been
an explosion of readily available commercial products infused with and marketing CBD contents, and yet
there is a paucity of information regarding the specific effects of CBD on immunity. Our laboratory is
interested in examining the effects of dietary choices on innate immunity, using the immortalized murine
macrophage cell line, RAW 264.7. The objective of this research was twofold. First, to determine if CBD
treatments would exert an observable effect on the murine macrophages when cultured in complete me-
dia. Therefore, identical experiments were conducted with two culture conditions, complete media versus
serum-free media, during CBD treatment. Second, to determine the effects of CBD on the proliferation, ac-
tivation, and inflammatory cytokine production in lipopolysaccharide (LPS)-activated murine macrophages
while also establishing a protocol for treating macrophages with CBD. Macrophage RAW 264.7 cells were
incubated with either control, 0.2, or 20 µM of CBD for 24 hours in serum-free media (SFM) or com-
plete media (CM), followed by a 6 hour, 0.01 or 1.0 µg/ml LPS challenge in SFM. Analyses were done
on total cells counts, cell viability and proliferation, as well as nitric oxide and pro-inflammatory cytokine
interleukin-6 (IL-6) concentrations in cell-conditioned media. We found that macrophages cultured in CM
during CBD treatments had higher percentages of live cells compared to those cultured in SFM with the
exception of SFM and 0.2 µM CBD treatment, in which percent live cells were comparable to CM percent
live counts. Additionally, culturing macrophages in CM, during CBD treatments, resulted in significantly
higher cell viability (MTS assay) compared to macrophages in SFM. There was no significant effect of
CBD or media type on nitric oxide production. At the highest CBD concentration,(20 µM) in SFM, in
addition to the lack of cell growth, proliferation and viability, cells became quiescent and ceased producing
inflammatory cytokine IL-6. Our results suggest that with high 20 µM concentrations of CBD, there is a
marked effect of decreased cell proliferation and pro-inflammatory IL-6 production.
Keywords: CBD · macrophage · inflammation
Introduction
Cannabidiol Molecule
The marijuana plant, Cannabis sativa, has a host of
derived molecules and cannabinoids that are of re-
search interest for their various functions and po-
tential health effects. Cannabidiol (CBD) is one
such molecule (Figure 1), and is not only the most
abundant nonpsychotropic plant cannabinoid, but
has been touted as an natural remedy for a vari-
ety of health issues such as chronic pain, insom-
nia and anxiety. Yet another derivative is ∆9-
tetrahydrocannabinol (THC) which is the major psy-
choactive ingredient and has also been implicated in
various immunomodulatory effects.
Usage of the marijuana plant by people for its
fibers, food, rituals, or believed health benefits dates
back to pre-Neolithic times (Clarke & Merlin, 2013).
However, twenty years ago, cannabinoids were being
researched by few and was of little interest to many
researchers. Reports from as early as the 1960s have
warned of the potential effects of cannabinoids such
as THC and CBD on human health and decreased
ability to resist infections (Pertwee, 2005). More re-
cently, there has been an increased growth in the
CBD oil market because of factors such as the le-
galization of cannabis-based products, leading to the
incorporation of its oil into our supplements, food,
and body care products (MarketWatch, 2019). In the
past THC has received considerably more attention
than CBD, the recent rise in commercialization and
more relaxed regulations have made CBD a topic of
interest in healthcare and commercial products alike.
Since, CBD’s specific effects on the body have only
recently started being explored the need for labora-
tory and clinical research on its specific effects has
risen.
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Figure 1: Cannabidiol Molecule
Inflammation
Macrophages are immune cells that scavenge for in-
vading pathogens and help link innate and adap-
tive immunity by stimulating lymphocytes and other
adaptive immune cells to respond to foreign in-
vaders. Macrophages help determine the extent, as
well as the type, of immune response that will be
mounted against an invading pathogen. Chemokines
and cytokines produced by macrophages help recruit
and activate other immune cells to the area where
the pathogen was encountered. One of the impor-
tant cytokines produced by macrophages is the pro-
inflammatory cytokine interleukin-6 (IL-6) (Janeway
et al., 2001). Interleukin-6 is multi-functional, acting
as a signaling molecule to hematopoietic stem cells,
hepatocytes and immune B cells (Matsuda & Kishi-
moto,1998). The importance of IL-6 in many physi-
ological functions makes it the perfect candidate for
the initial testing of the immune response to CBD.
Chronic inflammation has been implicated as a
cancer causing pathway through tissue destruction
and scarring, and reshaping of the tissue architecture
as well as contributing to changes in gene expression
that may result in tumorigenesis (Hunter, 2012). Un-
derstanding how inflammation can be mediated and
suppressed in some cases can allow us to curb the on-
set or even progression of these inflammation-related
diseases.
Suppression of the inflammatory response may pro-
vide relief for those suffering chronic pain but may
be dangerous for lowering the defenses against bac-
terial and other infections. Normal immune func-
tions is critical for surviving in an environment full
of pathogens and foreign organisms as well as deal-
ing with the internal risk factors such as autoimmune
diseases. It is recognized that the age-associated de-
cline in immunologic vigor directly or indirectly con-
tributes to increased susceptibility to infectious dis-
eases, meaning avoiding decreasing the inflammatory
response to a drastic extent may prove deadly (Wu et
al., 2008). Determining how inflammatory function
is affected by various factors, such as CBD and CBD
concentration, are important to understand in order
to decide how it would be used commercially and in
the healthcare setting.
Effects of Cannabidiol on Inflammation
With the potential benefits of CBD, there have been
studies done on various cell lines and mouse models
to test its immunomodulating effects. The proposed
immunomodulating effects of CBD are thought to be
related to its strong immunosuppressive effects due
to its ability to suppress the proliferation of lym-
phocytes and production of inflammatory proteins in
mice treated with high doses (Kaplan et al., 2008).
The way in which the CBD molecule is able to
have an immunomodulating effect on cells within
an organism is through the CB1 and CB2 recep-
tors. It has been discovered that the CB2 recep-
tor is mainly expressed in immune cells including
monocytes, the precursors to macrophages. Addi-
tionally, is has been found that in mouse monocytes
that a predominance of CB2 receptors resulted in a
stronger anti-inflammatory response, such as an inhi-
bition of chemotactic movement in response to mono-
cyte chemo-attractant protein 1 when stimulated by
cannabinoids (Han et al., 2009). Essentially, CBD
acts as an inverse antagonist at the CB2 receptors
meaning that it is able to inhibit the migration of
immune cells therefore exerting an anti-inflammatory
effect (Watt & Karl, 2017).
With the increase in legalization and interest in
the CBD molecule, it has been extensively studied
in the last decade. There is a current trend in the
medical industry to include CBD as a possible treat-
ment for many ailments, from neurologic disorders
like epilepsy and seizures to inflammatory and au-
toimmune diseases. There is current research on the
3
beneficial effects of CBD in animal models of mul-
tiple sclerosis, rheumatoid arthritis, diabetes, and
Alzheimer’s disease, among others (Kozela et al.,
2011; Malfait et al., 2000; Weiss et al., 2008; Watt
and Karl, 2017).
The benefit of decreased anti-inflammatory pro-
teins released from macrophages has also been tested
in diabetic mouse models. In young non-obese
diabetes-prone mice administered with CBD, symp-
toms of initial or latent diabetes stages were amelio-
rated and levels of pro-inflammatory cytokine IL-12
produced by splenocytes were significantly reduced
(Weiss et. al, 2008). Although there is plenty of sci-
entific literature using animal or cell-based immuno-
logical models for CBD research, the investigations
into the effects of CBD therapy on the immunity of
human subjects is quite limited. Past studies with
human subjects have primarily focused on healthy
individuals, rather than those suffering from chronic
disease, and the use of cannabis on circulating pro-
inflammatory cytokine concentrations in the blood
(National Academies of Sciences, Engineering, and
Medicine, 2017). With the continued research into
the effects of CBD in immunity and positive ther-
apeutic results, future directions may include more
human based studies.
Research Objectives
Culture Conditions The primary objective of
this research was to determine the appropriate
methodology and protocol for treating murine
macrophages with physiological concentrations of
CBD in vitro. Since we did not know if CBD would
only be taken up by serum-starved cells we designed
the experiments to test complete versus serum-free
media.
Effects on Inflammation If CBD can suppress
inflammatory molecule production in murine mod-
els then it makes sense to research its immunomod-
ulating ability in mouse macrophages. The im-
portant question we ask is: do physiological doses
of CBD affect inflammatory parameters in mouse
macrophages? Therefore the secondary purpose
was to test the effects of CBD on the prolifera-
tion, activation, and inflammatory cytokine produc-
tion in lipopolysaccharide (LPS)-activated murine
macrophages.
Experimental Design
To test our first objective of creating a protocol to
determine if CBD would have a an observed effect
in complete media we created two distinct culture
conditions using complete media or serum-free media
for the duration of the CBD treatments. Serum-free
media lacks bovine serum albumin compared to com-
plete media. The activation of macrophages via LPS
was still done in SFM as the macrophage activation
efficacy of LPS is diminished in complete media.
In addition to the culturing of macrophages within
two different media types, the quality and quantity of
cells were analyzed as well as important inflammatory
markers, nitric oxide and pro-inflammatory cytokine
IL-6, were quantified from the conditioned media af-
ter LPS-stimulation. This was necessary in order to
address our secondary objective: measuring the con-
centration of the pro-inflammatory molecule IL-6 to
observe the potential immunomodulating effects of




Murine macrophages (RAW 264.7) were purchased
from ATCC (Manassass, VA). Dulbecco’s modified
Eagle’s medium (DMEM), phosphate buffered saline
(PBS), fetal bovine serum (FBS), and penicillin-
streptomycin were purchased from Fisher Scientific
(Pittsburg, PA). The cannabidiol molecule was ob-
tained from Cayman (item: 90081) suspended in
methanol. The methanol was replaced with ethanol
by drying out the methanol with N2 gas and reconsti-
tuting the CBD in 2 ml of pure ethanol. Lipopolysac-
charide for macrophage stimulation was obtained
from E. coli. The interleukin IL-6 enzyme-linked im-
munosorbent assays (ELISA) were purchased from
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R&D systems (Minneapolis, MN). Griess assay’s for
nitric oxide (NO) quantification and MTS assay for
cell proliferation quantification were obtained from
Promega (Madison, Wisconsin).
Cell Culture and Treatment
RAW 264.7 murine macrophages were cultured in
Gibco DMEM with 10% FBS and 1% penicillin-
streptomycin in polystyrene 6-well plates. Cells were
incubated at 37 ◦C in a humidified environment of
95% O2 5% CO2. Complete and serum-free media
were prepared the same with antibiotics for incu-
bation of macrophages, with the exception of SFM
which lacked bovine serum albumin compared to
complete media. Medium was changed every two
days and the cells were not grown beyond 80% conflu-
ency during expansion. Experiments were performed
with cells not surpassing 15 passages. For CBD treat-
ments, cells were grown until 80-90% confluence fol-
lowed by a 24 hour CBD treatment, either an ethanol
control, 0.2 µg/ml, or 20 µg/ml of CBD. Following
CBD treatment, supernatant was removed, cells were
washed twice with 1X PBS and serum-free media was
added along with 0.01 or 0.1 µg/ml of LPS. After a
6 hr incubation, cell-conditioned media was collected
and stored in -80◦C until NO, and IL-6 analysis. Cell
counts were performed immediately following the 6
hr LPS challenge. Experiments were conducted five
times.
Cell Proliferation Analysis
An MTS assay was run concurrently with each ex-
periment. Cells were seeded in a 96-well plate at an
initial concentration of 0.01∗106 cells per well. Once
a confluency of 80% was reached, macrophages were
treated with appropriate CBD concentrations of ei-
ther control, 0.2 µg/ml, or 20 µg/ml for 24 hrs. Sub-
sequently, after 6 hr LPS stimulation, CellTiter 96 R©
AQueous One Solution Reagent was added directly to
wells and incubated at 37 ◦C. Measurements were
taken at 1 and 2 hrs by Epoch spectrophotometer at
490 nm.
Cytotoxicity Analysis
During collection of cell conditioned media, 1 ml was
retained in the wells for cell scraping and cell counts.
From each well 100 µl of cells and 100 µl of try-
pan blue were mixed. From this mixture, 10µl were
applied to hemocytometer slides and inserted into
the CountessTM II FL cell counter (Fisher Scientific,
Pittsburgh, PA), to determine total concentration of
cells, percent live, and dead cells.
Nitric Oxide (NO) Concentration
Analysis of NO concentration in samples was done us-
ing a Griess Reagent kit, with samples tested in trip-
licate. The standard curve was used to extrapolate
the concentrations of NO from the samples. Mea-
surements were taken by Epoch spectrophotometer
at 548 nm.
IL-6 Concentration
Analysis of IL-6 in samples was done using enzyme-
linked immunosorbent assay (ELISA). Plates were
coated with capture antibody 24 hr before use with
samples tested in triplicate. The standard curve was
used to extrapolate the concentrations of IL-6 from
the samples.
Statistics
Results are expressed as a mean ± SEM. Nitric ox-
ide and percent live cells data were normalized us-
ing a log base 10 transformation, and ArcSin square
root, respectively. Concentrations of IL-6 and NO in
cell culture medium and were analyzed using Multi-
way split-plot ANOVA. When treatment effects were
detected (p < 0.05), means were separated using
Tukey’s HSD. For the IL-6, NO, percent live, MTS,
and total cells, the sources of variation included
experiment, treatment, experiment∗treatment, and
well(experiment∗treatment), with the experiment
considered a random variable. All statistical anal-
yses were performed using JMP Pro 14 while figures
and images were created via Tableau.
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Figure 2: Total cells measured by cell count of RAW 264.7 cells treated with 1.0 µg/ml LPS after CBD pre-
incubation (a) Average total number of cells counted in both serum-free and complete media and separated by CBD
treatment (p=0.03). (b) Average total number of cells counted separated by media type (p =0.003). Treatments were
compared using a split-plot ANOVA, followed by post-hoc Tukey-Kramer HSD. Significant differences are represented
with different letters (p < 0.05). Bars represent the mean ± pooled S.E.M. (n = 5).
Results
In our study, we evaluated the importance of com-
plete versus serum-free media in examining the effects
of CBD on various cytokines and cellular functions
in in vitro LPS-stimulated murine macrophage RAW
cells. In order to determine if maintaining the murine
macrophages in serum-free media during CBD incu-
bation would have an effect on cell viability RAW
264.7 cells were incubated with either control, 0.2, or
20 µM of CBD for 24 hour in serum-free media (SFM)
or complete media (CM), followed by a 6 hour, 0.01
or 1.0 µg/ml LPS challenge in SFM. These results
suggest that concentrations of 0.2 and 20 µM CBD
have significant effects on murine macrophage prolif-
eration (Figure 3), viability (Figure 2 & 4), and IL-6
production (Figure 6) in both complete media and
serum-free media.
Cell Viability
Amongst the CBD treatments, for both media types,
total cells counts were significantly affected (p =
0.033) by the 0.2 µM CBD treatment averaging
higher in cell counts than 20 µM CBD treatments
(12465375±2784496, 4944137±2784496)(Figure 2a).
However, both 0.2 and 20 µM CBD treatments were
not significantly different than the control containing
no CBD.
When comparing total cells by media type
treatment, cells grown in complete media dur-
ing CBD treatment incubation resulted in a sig-
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Figure 3: Cell proliferation measured by MTS of RAW 264.7 cells activated with LPS after CBD 24 hr pre-
incubation (a) Average cell proliferation measured in both media types for different CBD treatments (p < 0.0001)
(b) Calculated average cell proliferation separated by media type (p=0.0008). Treatments were compared using a
split-plot ANOVA, followed by post-hoc Tukey-Kramer HSD. Significant differences are represented with different
letters (p < 0.05). Bars represent the mean ± pooled S.E.M. (n = 4).
nificantly higher average cell count (12498542 ±
2556384, 5592883 ± 2556384; p = 0.003) than its
serum-free treatment counter part (Figure 2b). CBD
concentrations had similar effects on cell viability re-
gardless of media type on cell viability (CM control
13221750± 3377627, 0.2 µM 14805750± 3377627, 20
µM 13221750± 3377627 and SFM control 6233500±
3377627, 0.2 µM 10125000±3377627, 20 µM 420150±
3377627 total cells; p = 0.73).
Cell Proliferation
Cell proliferation was determined via MTS prolifera-
tion assay. Murine macrophages in both media types
treated with 20 µM CBD on average had significantly
lower proliferation than control or 0.2 µM treatments
(0.2±0.06, 0.69±0.06, 0.65±0.06; p < 0.0001) (Figure
3a).
When comparing the two media types, serum-free
media had an average proliferation of cells much
lower than cells cultured in complete media during
CBD treatment (0.38 ± 0.53 and 0.65 ± 0.53; p =
0.0008)(Figure 3b). There was no significant effect
of a media type and CBD treatment interaction on
cell proliferation (p = 0.09).
Cytotoxicity Analysis
Cytotoxicity of the CBD treatments and media
types was tested by using the Trypan blue exclu-
sion method to measure the percentage of murine
macrophage live cells (Figure 4). There was an in-
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Figure 4: Percent live RAW 264.7 cells after 6 hr LPS
challenge with CBD 24 hr pre-incubation. Average per-
centage of live cells divided by different media types and
CBD treatments. Complete media p = 0.92 while serum-
free media p = 0.002. Data was normalized using a√
arcsin transformation and treatments were compared
using a split-plot ANOVA, followed by post-hoc Tukey-
Kramer HSD. Significant differences are represented with
different letters (p < 0.05). Bars represent the mean ±
individual S.E.M. (n= 5).
teraction effect between media type and CBD treat-
ment (p = 0.0053) which was further analyzed by
media type to reveal that macrophages cultured in
complete media had no difference in percent live cells
across all CBD treatments (p = 0.92).
Meanwhile, cells grown in serum-free media had
significantly varied percent live counts based on CBD
treatment with the 0.2 µM CBD treatment result-
ing in much higher percent live cells than the control
and 20 µM CBD treatment (p = 0.0024). Over-
all, SFM+20 µM CBD treatment resulted in the
lowest percent live count. Macrophages cultured
in complete media had higher percentages of live
cells compared to those cultured in serum-free me-
dia (53.2±5.6% vs 35.2±5.6% live; p < 0.0001).
There was no significant effect of LPS concentra-
tion (0.1 versus 1.0 µg/ml) for stimulation (p = 0.45)
Figure 5: Nitric oxide production by RAW 264.7
cells treated 1.0 µg/ml with LPS after CBD 24 hr pre-
incubation. Calculated average of nitric oxide production
for both complete and serum-free media and separated by
CBD concentration (n= 4). Data was normalized using a
log transformation and treatments were compared using
a split-plot ANOVA. Bars represent the mean ± pooled
S.E.M (p < 0.05).
on test effects of CBD or media type.
Nitric Oxide (NO) Concentration
Nitric oxide levels were quantified in order to exam-
ine the activation level of the macrophages (Figure
5). There was no significant difference in NO pro-
duction from the RAW macrophages between CBD
treatment concentrations or media type (p = 0.52).
On average, amongst the three CBD treatment con-
centrations, cell production of nitric oxide averaged
0.55 ± 0.52.
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Figure 6: IL-6 concentrations in conditioned media produced by RAW 264.7 cells treated with 1.0 µg/ml LPS
after CBD pre-incubation (a) Average IL-6 produced calculated from both media types and separated by CBD
concentration (p = 0.038). (b) Average IL-6 produced with bars separated by CBD concentration within different
media types (p = 0.059).Treatments were compared using a split-plot ANOVA, followed by post-hoc Tukey-Kramer
HSD. Significant differences are represented with different letters (p < 0.05). Bars represent the mean ± pooled
S.E.M (n= 2).
IL-6 Concentration
Only experiments that stimulated macrophages us-
ing 1.0 µg/ml of LPS after CBD treatment were an-
alyzed for IL-6 production levels (n=2). On average,
between the two media types, the 20 µM CBD treat-
ment had significantly decreased cellular IL-6 pro-
duction compared to the control (43.7 ± 41.43 and
206.8 ± 41.7pg/106, p = 0.038, Figure 6a).
When CBD treatment effects were separated based
on media type, there was a trend that indicated
that in serum-free media, 20 µM CBD treatment re-
sulted in a complete elimination of IL-6 production
compared to control and 0.2 µM CBD treatments
(7.1∗10−14±57.4, 302.3±57.4, 239.6±57.4pg/106; p =
0.059, Figure 6b). Meanwhile, in complete-media and
CBD treated cells, there was no difference between
the IL-6 concentrations produced across all of the
CBD treatments. Overall, there was no significant ef-
fect of media type on cell IL-6 production (p = 0.09).
Discussion
Methodology
While drawing on past research into CBD’s effects
on other cell lines and ailments, our project aimed
to establish a protocol for the culturing and treat-
ment of murine macrophages with CBD while ob-
serving the effects of varying concentrations of CBD
on cell viability, proliferation, cytotoxicity, NO and
IL-6 production. This methodology will hopefully en-
able further research into CBD’s effects on murine
macrophages while also providing a useful tool for
analysis of additional specific cytokines that affect
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inflammation.
Based on the results of this study we would proceed
with the use of complete media for future experiments
testing the effects of CBD on murine macrophages.
In our previous work with fatty acids and murine
macrophages we used serum-free media as a means
of ensuring the delivery of our fatty acid treatment
into the cells. To determine if this was necessary
for CBD we chose to duplicate the CBD treatments
into two media type conditions, serum-free and com-
plete media. There was an observed effect of CBD on
macrophage function compared to the control in ex-
periments with the complete media condition. There-
fore it can be determined that cannabidiol has an
effect on macrophages with or without complete me-
dia. It is still necessary to utilize serum-free media
when conducting the macrophage LPS challenge post
CBD treatment as LPS is deactivated when used with
complete media.
Using complete media is favorable as on average,
experiments result in higher total cells, percent live
counts, and proliferation than those with serum-free
media. Cell proliferation was measured to have the
same effects for the CBD treatments regardless of
media-type, allowing us to choose the media type
based on the total cell and percent live differences.
However, within our IL-6 results, differences between
CBD concentrations are more easily observed in the
SFM. In previous research using complete media and
CBD pre-treatments on murine macrophages, Rajan
et al.(2016) performed 2 hour 5 µM CBD treatments
followed by 24 hr LPS stimulation. A longer LPS
stimulation may be necessary for future complete me-
dia CBD treatment experiments to see more observ-
able differences between cytokine production levels.
Based on our results of this study it can be expected
that future CBD experiments using complete media
should result in similar percent live values across dif-
ferent CBD treatments in the 0.2 to 20 µM concen-
tration range. Additionally, cells grown in serum-free
media during the CBD pre-treatment period did not
grow as much as those grown in complete media dur-
ing this period which proves difficult to measure cy-
tokine levels when there are minimal cells producing
them.
CBD effects
These results suggest that in general, concentrations
of 0.2 and 20 µM CBD have no detrimental effects
on murine macrophage viability. We are unable to
conclude on the result of the nitric oxide assay as
there were no significant effects due to large variabil-
ity of measured nitric oxide concentrations for each
treatment and media type.
We are able to see that for percent live cells in
complete media, there is no evident cytotoxic effect
of the higher concentration of 20 µM CBD. With the
serum-free media there is significantly lower percent
live cells but this is also in combination with a gen-
eral lack of total cells and significantly lower prolifer-
ation levels (MTS assay) signifying a lack of growth
of cells and cell death. It is known that cannabinoid
receptors modulate several signalling pathways that
are directly involved in the control of cell prolifera-
tion and survival. For example, various cannabinoids
have been found to exert an antiproliferative action
on a wide spectrum of cultured tumor cells (Pertwee,
2005). With this lack of cells in the SFM+20µM CBD
treatment, it is understandable why IL-6 production
is decreased to almost zero. Therefore, the 20 µM
CBD concentration is not more cytotoxic than 0.2
µM CBD concentrations but, for the higher concen-
tration there is a decrease in proliferation as well as
a decrease in the inflammatory cytokine IL-6. These
effects can be translated to positive results for certain
ailments, for it has been observed that in pre-diabetic
mice treated with CBD, there was a significant de-
crease of IL-6 in mouse plasma, as well as a decrease
in risk of diabetes development in adulthood (Weiss
et al., 2009).
When comparing total cell with MTS proliferation
data, there is a pattern in the effect of CBD concen-
tration on the average values, with the exception of
a slight increase in 0.2 µM CBD treated total cells
counts compared to the MTS data which has lower
proliferation for the same treatment. At the high 20
µM CBD concentration, cells became quiescent and
stopped producing inflammatory cytokine IL-6 in ad-
dition to the lack of cell growth, proliferation and
viability. In encephalitogenic MOG-specific T cells
treated with CBD, there was an antiproliferatory ef-
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fect in antigen-induced cell proliferation (Kozela et
al., 2011). These RAW macrophages were also stimu-
lated via LPS antigens after CBD treatment and dis-
play a similar inhibitory effect on proliferation, espe-
cially with increased concentrations of 20 µM CBD.
It may be possible to increase the effectiveness of
the CBD molecule by altering its binding ability to
the CB1 and CB2 receptors. An experiment was con-
ducted in which four derivatives of CBD were tested
for their ability to modulate NO, TNF-α, reactive
oxygen intermediates and their binding to CB1. Two
of the derivatives showed an increased suppressive ef-
fect of these inflammatory markers which may be a
path for developing therapeutic agents to modulate
nitric oxide and TNF-α production (Ben-Shabbat et
al., 2006).
Conclusion
The study of the effects of the cannabidiol molecule
are a quickly developing field and the need for un-
derstanding how to culture cells with this molecule is
the most basic of information needed to proceed. We
have been able to determine a methodology for the
culture and treatment of murine macrophages with
different concentrations of CBD. The establishment
of this methodology of using complete media has pro-
vided us with the groundwork for our initial findings
into the variable effects of different CBD concentra-
tions on the functions and cytokine production of
murine macrophages.
Future Directions
With this exploration we have identified the effects
of CBD on a few specific cellular markers, and the
pro-inflammatory cytokine IL-6. Nevertheless, there
are many other cytokines that macrophages produced
that impact inflammatory as well as other important
biological pathways. By using the protocol we es-
tablished for culturing macrophages with CBD we
can now examine these other cytokines. One such
macrophage product that is of interest to us is TNF-
α because suppression of it inhibits inflammatory
damage. Additionally, the cannabinoid receptor CB2
found mainly on immune cells has a role in modulat-
ing cytokine release and is a target of interest for us
(Pertwee, 2005). Finally, we have raised the question:
do physiological doses of CBD affect inflammatory
parameters in mouse macrophages and adipocytes?
We will work to observe inflammatory molecule pro-
duction by adipocytes and macrophages, separately,
as well as co-incubated after treatment with CBD.
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